105P Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study. (December 2022) - Jin, P.; Gao, Y.; Fu, Z.; Yang, W.; Meng, X.